BR112023022493A2 - Anticorpos para tratamento e prevenção de covid-19 e variantes emergentes - Google Patents

Anticorpos para tratamento e prevenção de covid-19 e variantes emergentes

Info

Publication number
BR112023022493A2
BR112023022493A2 BR112023022493A BR112023022493A BR112023022493A2 BR 112023022493 A2 BR112023022493 A2 BR 112023022493A2 BR 112023022493 A BR112023022493 A BR 112023022493A BR 112023022493 A BR112023022493 A BR 112023022493A BR 112023022493 A2 BR112023022493 A2 BR 112023022493A2
Authority
BR
Brazil
Prior art keywords
antibodies
covid
prevention
treatment
spike protein
Prior art date
Application number
BR112023022493A
Other languages
English (en)
Inventor
D Ho David
S Nair Manoj
Yaoxing Huang
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of BR112023022493A2 publication Critical patent/BR112023022493A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

anticorpos para tratamento e prevenção de covid-19 e variantes emergentes. a presente invenção refere-se a uma proteína spike (s) recombinante da variante b.1.351.2-7 do vírus sars-cov-2, a sequências de nucleotídeo de dna e rna codificando a proteína spike recombinante de b.1.351.2-7 e anticorpos engenheirados que se ligam à proteína spike de b.1.351.2-7 e neutraliza o vírus b.1.351.2-7.
BR112023022493A 2021-04-28 2022-04-27 Anticorpos para tratamento e prevenção de covid-19 e variantes emergentes BR112023022493A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163181138P 2021-04-28 2021-04-28
PCT/US2022/026516 WO2022232255A2 (en) 2021-04-28 2022-04-27 Antibodies for the treatment and prevention of covid-19 and emerging variants

Publications (1)

Publication Number Publication Date
BR112023022493A2 true BR112023022493A2 (pt) 2024-02-15

Family

ID=83847292

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022493A BR112023022493A2 (pt) 2021-04-28 2022-04-27 Anticorpos para tratamento e prevenção de covid-19 e variantes emergentes

Country Status (10)

Country Link
EP (1) EP4330279A2 (pt)
JP (1) JP2024518151A (pt)
KR (1) KR20240001181A (pt)
CN (1) CN117616040A (pt)
AU (1) AU2022267248A1 (pt)
BR (1) BR112023022493A2 (pt)
CA (1) CA3218058A1 (pt)
CO (1) CO2023016033A2 (pt)
IL (1) IL308042A (pt)
WO (2) WO2022232262A2 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210899B1 (en) * 1994-11-04 2001-04-03 The Procter & Gamble Company Use of a BMP protein receptor complex for screening bone metabolism actives and cells co-transfected with a type II BMP receptor and type I BMP receptor
NZ750974A (en) * 2016-09-16 2024-01-26 Bionomics Ltd Antibody and checkpoint inhibitor combination therapy
EP4034556A1 (en) * 2019-09-26 2022-08-03 Amgen Inc. Methods of producing antibody compositions
US10787501B1 (en) * 2020-04-02 2020-09-29 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

Also Published As

Publication number Publication date
KR20240001181A (ko) 2024-01-03
WO2022232262A2 (en) 2022-11-03
JP2024518151A (ja) 2024-04-25
CA3218058A1 (en) 2022-11-03
AU2022267248A1 (en) 2023-11-09
EP4330279A2 (en) 2024-03-06
CO2023016033A2 (es) 2023-12-11
WO2022232255A3 (en) 2022-12-22
WO2022232262A3 (en) 2022-12-01
CN117616040A (zh) 2024-02-27
IL308042A (en) 2023-12-01
WO2022232255A2 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
BR112019022515A2 (pt) Agentes de anticorpo direcionados contra o gene 3 de ativação linfocitária (lag-3) e usos dos mesmos
CL2023000705A1 (es) Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
BR112022016346A2 (pt) Vacina ncov-2019 (sars-cov-2)
BR112014016361A2 (pt) ácido nucleico que compreende ou codifica uma alça peduncular de histona e uma sequência poli(a) ou um sinal de poliadenilação para aumentar a expressão de um antígeno patogênico codificado
CL2019001049A1 (es) Vacuna contra parvovirus porcino.
AR083740A1 (es) Anticuerpos dkk1 (dickkopf-1) y metodos de uso
BR112022007677A2 (pt) L-asparaginase recombinante
PE20190420A1 (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas
BRPI0510016A (pt) vetor lentiviral recombinante para expressão de uma proteìna de flaviviridae e aplicações do mesmo como vacina
BRPI0312173B8 (pt) vetor e processo para a preparação de partículas infecciosas de vírus do sarampo
PE20181176A1 (es) Composiciones biofarmaceuticas
CR20220618A (es) Nuevas proteinas de unión a repeticiones de anquirina y sus usos
ECSP10010082A (es) Udp-glucuronil transferasa y polinucleotido de codificacion
PE20230171A1 (es) Vacunas contra el coronavirus y metodos de uso
MX2021013743A (es) Subunidad s1 modificada de la proteina de espicula de coronavirus.
CL2022003491A1 (es) Moléculas de anticuerpo contra el virus bk
BR112023022493A2 (pt) Anticorpos para tratamento e prevenção de covid-19 e variantes emergentes
BR112018072719A2 (pt) molécula de ácido nucleico isolada, composição, e, métodos de indução de uma resposta imune contra o filovírus e o ebolavirus, de tratamento de um indivíduo que foi diagnosticado com ebolavirus e de prevenção da infecção por ebolavirus
BRPI0512393A (pt) vacinação de jaritataca e/ou mangusto contra raiva
DE60325838D1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine
MX2022015489A (es) Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus.
CO2021005066A2 (es) Vacuna de ibv 4/91 con proteína espicular heteróloga
ATE497978T1 (de) Pharmazeutische zusammensetzungen von antikörpern von viruserkrankungen
BR112022023135A2 (pt) Amidas tricíclicas substituídas, análogos das mesmas e métodos que usam as mesmas